Bone and muscle mass characteristics in patients with gastroenteropancreatic neuroendocrine neoplasms
Endocrine · 2024
DOI: 10.1007/s12020-024-04140-4 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endocrine, 2024. Verfasst von Charalampos Aktypis und 6 weiteren Autor:innen. Beteiligte Einrichtung: Academic Department of Gastroenterology, Medical School of National and Kapodistrian University of Athens, Laiko General Hospital, Athens, Greece. ak…. Hauptthemen laut MEDLINE: Neuroendocrine Tumors, Bone Density, Pancreatic Neoplasms, Stomach Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 59 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Neuroendocrine neoplasms (NEN) are rare tumors arising from neuroendocrine cells most commonly in the gastrointestinal-tract. In recent years, advancements in therapeutics have increased survival rates in patients with NEN leading to a greater clinical burden compared to the general population. METHODS: The aim of this single-center case-control study was to investigate the incidence of low bone mass and changes in body composition in adult patients diagnosed with gastroenteropancreatic neuroendocrine tumors (GEPNET). Enrolled participants underwent measurements of bone mineral density (BMD) at the lumbar spine (LS), femoral neck (FN), and total hip (TH) and body composition analysis with calculation of total fat-mass (TFM) and relative skeletal mass index (RSMI), by dual X-ray absorptiometry. RESULTS: Ninety GEPNET patients (28 with Pancreatic-NET, 20 with small-intestine-NET, 42 with gastric-NET), and 50 age and sex-matched controls were enrolled. The mean disease duration was 5±4.4 years, the majority of patients (54/90) was classified as stage-1, and were not receiving systemic-treatment (76/90). The incidence of osteoporosis/osteopenia was threefold higher in the patients' cohort, compared to controls (OR: 3.17 95% CI 1.16-7.8, p < 0.001). Among NEN patients, gastric-NET had the lowest bone mass, especially in LS. In addition, GEPNET patients demonstrated significantly lower TFM and RSMI, compared to controls (TFM: 31.6 ± 9.6 kg vs. 38.6 ± 6.4 kg, respectively, p = 0.03; RSMI: 6.4 ± 1.1 vs. 8.2 ± 0.6, respectively, p < 0.001). Within our patients' cohort, RSMI was significantly associated with LS-BMD (rho = 0.49, p < 0.001) and TH-BMD (rho = 0.58, p < 0.001), and TFM was associated with TH-BMD (rho = 0.31, p = 0.004). CONCLUSIONS: Patients with GEPNET even at an early stage exhibit significantly lower bone, muscle and fat mass compared to the non-NET population, highlighting the importance of continuous monitoring of the musculoskeletal system in these patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Academic Department of Gastroenterology, Medical School of National and Kapodistrian University of Athens, Laiko General Hospital, Athens, Greece. aktypis.gastro@gmail.com.
- Εndocrinology Unit, First Department of Propaedeutic and Internal Medicine, National and Kapodistrian University of Athens, Medical School, Athens, Greece.
- Research Unit of Radiology and Medical Imaging, 2nd Department of Radiology, Attikon General University Hospital, School of Medicine, National and Kapodistrian, University of Athens, 115 27, Athens, Greece.
- Laboratory of Dietetics and Quality of Life, Department of Food Science and Human Nutrition, Agricultural University of Athens, Athens, Greece.
- Academic Department of Gastroenterology, Medical School of National and Kapodistrian University of Athens, Laiko General Hospital, Athens, Greece.
Zitieren
APA
Aktypis, C., Yavropoulou, M. P., Efstathopoulos, E., Polichroniadi, D., Poulia, K. A., Papatheodoridis, G., & Kaltsas, G. (2024). Bone and muscle mass characteristics in patients with gastroenteropancreatic neuroendocrine neoplasms. Endocrine. https://doi.org/10.1007/s12020-024-04140-4
Vancouver
Aktypis C, Yavropoulou MP, Efstathopoulos E, Polichroniadi D, Poulia KA, Papatheodoridis G, et al. Bone and muscle mass characteristics in patients with gastroenteropancreatic neuroendocrine neoplasms. Endocrine. 2024. doi:10.1007/s12020-024-04140-4
BibTeX
@article{Aktypis2024,
author = {Aktypis, Charalampos and Yavropoulou, Maria P and Efstathopoulos, Efstathios and Polichroniadi, Despina and Poulia, Kalliopi Anna and Papatheodoridis, George and Kaltsas, Gregory},
title = {Bone and muscle mass characteristics in patients with gastroenteropancreatic neuroendocrine neoplasms},
journal = {Endocrine},
year = {2024},
doi = {10.1007/s12020-024-04140-4}
}
EUVIMED